Messenger RNA therapy developer Moderna Therapeutics, which counts AstraZeneca and Alexion as backers is now valued at $7.5bn.

Moderna Therapeutics, a US-based RNA therapeutics developer backed by pharmaceutical firm AstraZeneca, raised $500m yesterday from investors including Alexandria Venture Investments, a branch of life sciences real estate trust Alexandria Real Estate Equities.

Financial services provider Julius Baer, Fidelity Management & Research, BB Biotech, Sequoia Capital China, Pictet, Viking Global Investors and ArrowMark Partners also took part.

The investors were filled out by the Singapore government-owned EDBI and Abu Dhabi Investment Authority, a sovereign wealth fund owned by the emirate…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?